EPISODE · Jun 2, 2026 · 31 MIN
Episode 498: Do You Want a One and Done Cholesterol Infusion? The Long Road Ahead
from Heart Doc VIP with Dr. Joel Kahn
Dr. Joel Kahn dives into a groundbreaking Phase 1 trial of Verve 102, a one-time intravenous gene-editing treatment that silences the PCSK9 gene to produce lasting LDL cholesterol reduction. Among 35 participants, the high-dose group saw LDL drop by 62% with mostly mild side effects — promising results, though Phase 2 and 3 trials and 15 years of follow-up still lie ahead. Also covered: updated colorectal cancer screening guidelines now starting at age 45, healthy lifestyle habits cutting mortality risk in cancer survivors by one-third, real-world weight regain data after stopping GLP-1 medications, why your B12 "normal" range may be too low, a blood test that may predict Alzheimer's years in advance, and a longevity preparedness tool from MIT AgeLab. Sponsored by Igennus — visit igennus.com/drkahn for 20% off.
NOW PLAYING
Episode 498: Do You Want a One and Done Cholesterol Infusion? The Long Road Ahead
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m